rs776746 (6986A>G) is a single nucleotide polymorphism in the CYP3A5 gene. The G change (often called CYP3A5*3) creates an alternative splice signal that typically produces little or no functional CYP3A5 protein; the A allele is associated with preserved enzyme expression. This variant was identified in pharmacogenetic studies that linked genotype to enzyme activity and drug clearance differences across populations. CYP3A5 is a member of the cytochrome P450 family, expressed in liver and extrahepatic tissues. It contributes to the oxidative metabolism of many xenobiotics and certain endogenous steroids. Variation in CYP3A5 activity alters how quickly substrates are processed and can influence circulating levels of medications and metabolic intermediates important to cardiovascular physiology.

Results that indicate higher CYP3A5 activity (presence of the functional A allele) suggest greater capacity to metabolize CYP3A5 substrates. In practice this can be associated with faster clearance of certain drugs and differences in steroid handling. Results indicating lower or absent CYP3A5 activity (the 6986G/*3 allele) suggest reduced enzyme expression and slower metabolism of CYP3A5 substrates. Neither result is a standalone diagnosis; interpretation is most meaningful when combined with medication history and the other Cardio Zoomer biomarkers that reflect metabolic, inflammatory, and vascular status.

CYP3A5 – 6986A>G is included in Cardio Zoomer to provide pharmacogenomic context for cardiovascular care. It flags inherited differences in drug and steroid metabolism that can influence biomarker levels, medication response patterns, and downstream cardiovascular pathways, helping clinicians interpret the full panel more precisely.